MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • MDS Virtual Congress 2021

    Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?

    R. Hauser, S. Goud, A. Formella (Tampa, USA)

    Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…
  • MDS Virtual Congress 2021

    CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

    P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)

    Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…
  • MDS Virtual Congress 2021

    Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions

    K. Lyons, R. Pahwa, N. Crouse, L. Llorens, R. Howard, A. Formella (Kansas City, USA)

    Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…
  • MDS Virtual Congress 2021

    IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH

    R. Rose, E. Mitchell, H. Geerts (Sheffield, United Kingdom)

    Objective: To mitigate clinical variability of Time-Off with various therapeutic combinations Background: There is increasing interest to use wearable-based digital health measures to continuously monitor…
  • MDS Virtual Congress 2021

    CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis

    M. Saint-Hilaire, A. Corbin, P. Zhao, D. Kegler-Ebo (Boston, USA)

    Objective: A meta-analysis of PGIC results was performed using combined data from 3 different studies of CVT-301 in patients with PD over a total of…
  • MDS Virtual Congress 2021

    Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease

    C. Tanner, J. Lytle, A. Formella (San Francisco, USA)

    Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…
  • MDS Virtual Congress 2021

    Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results

    T. Fay-Karmon, N. Galor, B. Heimler, R. Bartsch, A. Zilka, V. Livneh, M. Plotnik, S. Hassin-Baer (Ramat Gan, Israel)

    Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…
  • MDS Virtual Congress 2021

    Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…
  • MDS Virtual Congress 2021

    Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications

    D. Kremens, W. Oertel, R. Pahwa, R. Hauser, C. Lecureuil, R. Johnson, G. Went (Philadelphia, USA)

    Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…
  • MDS Virtual Congress 2020

    Freezing of gait that persists from the OFF to the ON state is associated with memory impairments in Parkinson’s disease

    J. McKay, F. Goldstein, B. Sommerfeld, D. Bernhard, S. Factor (Atlanta, GA, USA)

    Objective: To examine cognitive correlates associated with FOG that persists in both the ON and OFF medication states (ONOFF-FOG) vs. FOG that appears only in…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • An atypical and interesting feature of Parkinson´s disease
  • #24970 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley